Xilio Therapeutics (XLO) Revenue & Revenue Breakdown
Xilio Therapeutics Revenue Highlights
Latest Revenue (Q)
$2.36M
Xilio Therapeutics Revenue by Period
Xilio Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Xilio Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Xilio Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $2.36M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.90M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Xilio Therapeutics generated $2.36M in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Xilio Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAG | Adagene | $18.11M | $833.34K |
| IKNA | Ikena Oncology | $9.16M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| DSGN | Design Therapeutics | - | - |
| RAPT | RAPT Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| CNTB | Connect Biopharma | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| TYRA | Tyra Biosciences | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
| CSBR | Champions Oncology | - | $12.02M |
XLO Revenue FAQ
What is Xilio Therapeutics’s yearly revenue?
Xilio Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. XLO's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Xilio Therapeutics’s quarterly revenue?
Xilio Therapeutics's quarterly revenue for Q2 2024 was $2.36M, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). XLO's quarterly revenue for Q4 2023 was $2.9M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Xilio Therapeutics’s revenue growth rate?
Xilio Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.